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Commentary on: Alcohol Intake Increases High-grade Prostate Cancer Risk Among Men Taking
Dutasteride in the REDUCE Trial. Fowke JH, Howard L, Andriole GL, Freedland SJ. Eur Urol.
2014 Feb 9 (E-pub on line)
______________________________________________________________
Stand first
Two major trials, PCPT and REDUCE, used 5 alpha-reductase inhibitors to determine the
impact on the subsequent diagnosis of prostate cancer. Both showed that high alcohol intake
significantly increased prostate cancer risk among men randomized to the treatment arms. The
recommendation that patients eliminate alcohol when taking 5 alpha-reductase inhibitors seems
appropriate.
_____________________________________________________________
Fowke and associates have reviewed data from the Reduction by Dutasteride of Prostate
Cancer Events (REDUCE) trial relating to alcohol consumption patterns in the study (1). The
REDUCE trial evaluated the effect of 5 alpha-reductase inhibitor (5-ARI) dutasteride on
subsequent cancer diagnosis in a group of men with a prior negative biopsy (2). They found that
alcohol intake was not associated with increased prostate cancer for men in the placebo arm of
the study, adding support to the fact that alcohol intake is unrelated to prostate cancer risk.
However, for men on dutasteride, the relationship of alcohol intake and prostate risk was far
more complex. While alcohol intake was not associated with more low-grade prostate cancer for
men on dutasteride, increased alcohol intake when combined with dutasteride increased the risk
of high-grade prostate cancer. Among men randomized to dutasteride or placebo in the
REDUCE trial, it appears that alcohol consumption negated the protective association between
dutasteride and high-grade prostate cancer.
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The use of alcohol has been associated with increased mortality risk for several cancers
in men, but only for those with moderate and heavy drinkers based on a meta-analysis by Jin
and associates (3). Heavy drinking in this meta-analysis was defined as > 50gm/day with light
drinking at a level of ≤12.5 g/day being mildly protective of overall mortality. The risk of cancers
of the oral cavity, larynx, and pharynx rise linearly with alcohol consumption. Heavy drinking is
also known to be associated with pancreatic and hepatocellular cancers.
The authors note most cohort and case-control studies report no evidence of an
association between alcohol use and prostate cancer. Other random studies that draw an
association have been inconsistent. What is most provocative about this dutasteride based
study is that the Prostate Cancer Prevention Trial (PCPT) found the highest category of alcohol
intake was associated with increased risk of both low-grade (Gleason <7) and high-grade
(Gleason >7) prostate cancer at follow-up biopsy but only among men taking the 5 alphareductase inhibitor finasteride (4). PCPT was also a prostate cancer prevention trial that used
finasteride as the active agent (5). The findings from PCPT are consistent with the current
Fowke study. Taken together, this suggests a possible class effect of 5 alpha-reductase
inhibitors with alcohol interaction possibly increase the risk of prostate cancer.
A recent review notes that there are no long-term randomized trials of alcohol on overall
clinical outcomes and alcohol consumption (6). There is strong evidence of causality based
upon epidemiologic studies and short-term trials that have found beneficial effects of alcohol on
cardiovascular risk factors with an increased risk of several cancers in men as noted. It remains
possible that some of the health benefits and risks of alcohol consumption represent
associations unrelated to the intake of alcohol itself but relate to the interaction between alcohol
and other modifying factors. This study by Folke and associates adds validity to this observation
concerning other modifying factors. In this case the 5-alpha reductase inhibitor seems to be
modifying high grade prostate cancer risk. Other modifying factors on the diagnosis of high
grade cancer such as statin use have been reviewed in the REDUCE data set. Statins were not
associated with any prostate cancer including high-grade disease (7).
This effect of increased prostate cancer risk while on dutasteride is potentially explained
by several concepts. One focuses on the fact that ethanol metabolism increases oxidative
stress that may ultimately impact on prostate cancer initiation and progression. Other theories
relate to hormonal changes such as increased estrogen with heavy alcohol consumption and
other metabolic changes such as increased insulin levels or folate depletion that create a procarcinogenic effect. It should be noted that these are plausible theories that have not been
proven.
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The goal of the Fowke paper was to confirm an association between alcohol
intake and cancer that was determined in the PCPT trial using data from the REDUCE trial. The
interaction between alcohol, prostate cancer and 5 alpha reductase inhibitors in these
retrospective analysis appears to be real. This raises the concern that men taking 5 alpha
reductase inhibitors for symptomatic benign prostatic hypertrophy might potentially increase the
risk of prostate cancer. The recommendation by the authors that patients consider elimination of
alcohol when taking 5α-reductase inhibitors seems appropriate.
_____________________________________________________________________
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